Danaher (DHR) Rating Reiterated by Credit Suisse Group
Danaher (NYSE:DHR)‘s stock had its “hold” rating reissued by research analysts at Credit Suisse Group in a report issued on Tuesday. They presently have a $99.00 price objective on the conglomerate’s stock. Credit Suisse Group’s target price suggests a potential upside of 4.63% from the stock’s previous close.
Several other research analysts have also recently issued reports on the company. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $95.00 price objective on shares of Danaher in a research report on Friday, September 8th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research report on Thursday, October 5th. Morgan Stanley reiterated an “overweight” rating and issued a $95.00 price objective (up previously from $86.00) on shares of Danaher in a research report on Friday, October 6th. Cowen restated a “buy” rating and issued a $90.00 price target on shares of Danaher in a research report on Wednesday, October 4th. Finally, Robert W. Baird raised their price target on Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Danaher presently has an average rating of “Buy” and a consensus price target of $94.38.
Danaher (DHR) opened at $94.62 on Tuesday. The stock has a market capitalization of $65,650.00, a price-to-earnings ratio of 24.26, a price-to-earnings-growth ratio of 2.23 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00. Danaher has a 52-week low of $77.66 and a 52-week high of $95.16.
In other news, CAO Robert S. Lutz sold 11,189 shares of the firm’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $91.66, for a total value of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now owns 18,314 shares in the company, valued at $1,678,661.24. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of Danaher stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total value of $11,671,620.96. Following the sale, the chief executive officer now owns 271,737 shares of the company’s stock, valued at approximately $25,173,715.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 273,810 shares of company stock valued at $25,218,813. Company insiders own 12.20% of the company’s stock.
A number of institutional investors have recently bought and sold shares of DHR. GQG Partners LLC purchased a new stake in Danaher during the 2nd quarter worth about $101,000. Zions Bancorporation increased its position in Danaher by 118.3% during the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after purchasing an additional 667 shares in the last quarter. Patten Group Inc. increased its position in Danaher by 262.3% during the 3rd quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after purchasing an additional 3,497 shares in the last quarter. Monetary Management Group Inc. increased its position in Danaher by 10.7% during the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after purchasing an additional 150 shares in the last quarter. Finally, Acrospire Investment Management LLC increased its position in Danaher by 185.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after purchasing an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 76.05% of the company’s stock.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.